Nurix Therapeutics, Inc. (NASDAQ:NRIX) stock is up during Monday’s premarket session as the company collaborates with Roche Holdings AG (OTC:RHHBY) to co-develop and co-commercialize bexobrutideg, an investigational Bruton’s Tyrosine Kinase (BTK) degrader.

The partnership aims to enhance treatment options for patients with B-cell malignancies, a sector projected to grow significantly, with the combined market expected to reach $41 billion by 2031.

The collaboration with Roche will focus on bexobrutideg, which is set to enter Phase 3 clinical trials for treating chronic lymphocytic leukemia (CLL) in the summer of 2026.

The partnership is seen as a strategic move to leverage Roche’s strengths in hematology and expand Nurix’s pipeline into immunology and neurology.

Deal Terms

Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million ...